Next Article in Journal
Blood Translation Elongation Factor-1δ Is a Novel Marker for Cadmium Exposure
Previous Article in Journal
Secretory Phospholipases A2 in Durum Wheat (Triticum durum Desf.): Gene Expression, Enzymatic Activity, and Relation to Drought Stress Adaptation
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2013, 14(3), 5170-5181;

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma

Department of Biopathology, Centre Hospitalier Universitaire de Montpellier, Montpellier 34000, France
Faculté de Médecine de Montpellier, Université de Montpellier I, Montpellier 34000, France
Department of Surgery, Centre Hospitalier Universitaire de Montpellier, Montpellier 34000, France
Department of Biostatistic, CRLC Val d'Aurelle, Montpellier 34000, France
Author to whom correspondence should be addressed.
Received: 7 February 2013 / Revised: 20 February 2013 / Accepted: 25 February 2013 / Published: 4 March 2013
(This article belongs to the Section Biochemistry, Molecular and Cellular Biology)
View Full-Text   |   Download PDF [741 KB, uploaded 19 June 2014]


Accumulation of molecular alterations, including EGFR overexpression and mutations in KRAS and BRAF, contribute to colorectal carcinogenesis. Since intestinal-type adenocarcinoma (ITAC) of the nasal cavity and paranasal sinus has morphologic and phenotypic features that are usually indistinguishable from colorectal cancer (CRC), it is likely that both tumor types share equivalent genetic alterations. Data from a series of 43 patients treated surgically for ITAC in Montpellier, France between November 1998 and December 2012 were collected. Tumors were characterized for mutations in KRAS and BRAF as well as EGFR overexpression. Kaplan-Meier survival curves were constructed using overall survival as the primary end points. Patient survival was analyzed using the hazards ratio. Twenty seven tumors (63%) showed EGFR positivity and 30% exhibited a high expression level (+2/+3). KRAS mutations were detected in 43% of cases. BRAF mutations were identified in 3.6% of specimens. Patients with age superior to 60 years, metastatic status, and KRAS mutations had significant overall survival values (p = 0.026, p = 0.001 and p = 0.03, respectively). Our results indicate that KRAS mutations and EGFR expression are frequent in ITAC and that KRAS mutations predict good patient prognosis in ITAC. Finally, EGFR directed molecular treatments could be investigated in a subset of patients affected by ITAC. View Full-Text
Keywords: ITAC; KRAS; BRAF; EGFR expression; prognosis marker ITAC; KRAS; BRAF; EGFR expression; prognosis marker
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Szablewski, V.; Solassol, J.; Poizat, F.; Larrieux, M.; Crampette, L.; Mange, A.; Bascoul-Mollevi, C.; Costes, V. EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. Int. J. Mol. Sci. 2013, 14, 5170-5181.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top